secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2022-06-23T23:59:59+00:00
Accession:  0001193125-22-179235
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics appoints Carrie Melvin as COO, effective June 21, 2022
----------------------------------------------------------------------------

- Carrie Melvin named COO; previously SVP Clinical Development at X4 Pharmaceuticals (Nasdaq: XFOR).
- Base salary $425K, sign-on bonus $60K, target bonus 40% of base salary.
- Receives inducement option for 210,000 shares vesting over 4 years (25% at 1-year cliff).
- Melvin brings 20+ years experience from GSK, TESARO, and Kura Oncology.
- Position is newly created; company advancing late-stage clinical development for TED programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/0001193125-22-179235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/d318381d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-179235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer